JP2020500182A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020500182A5 JP2020500182A5 JP2019523772A JP2019523772A JP2020500182A5 JP 2020500182 A5 JP2020500182 A5 JP 2020500182A5 JP 2019523772 A JP2019523772 A JP 2019523772A JP 2019523772 A JP2019523772 A JP 2019523772A JP 2020500182 A5 JP2020500182 A5 JP 2020500182A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- membered
- heterocyclyl
- carbocyclyl
- fibrosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 31
- 125000000623 heterocyclic group Chemical group 0.000 claims 21
- 125000004452 carbocyclyl group Chemical group 0.000 claims 20
- 125000003545 alkoxy group Chemical group 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000005843 halogen group Chemical group 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- -1 cyano, hydroxyl Chemical group 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 229940124530 sulfonamide Drugs 0.000 claims 12
- 150000003456 sulfonamides Chemical class 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 11
- 125000004438 haloalkoxy group Chemical group 0.000 claims 11
- 125000001188 haloalkyl group Chemical group 0.000 claims 11
- 206010016654 Fibrosis Diseases 0.000 claims 10
- 125000004103 aminoalkyl group Chemical group 0.000 claims 10
- 230000004761 fibrosis Effects 0.000 claims 10
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 9
- 150000001408 amides Chemical class 0.000 claims 9
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 5
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 125000004043 oxo group Chemical group O=* 0.000 claims 5
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 4
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 4
- 230000001575 pathological effect Effects 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 230000001476 alcoholic effect Effects 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000005884 carbocyclylalkyl group Chemical group 0.000 claims 2
- 230000009787 cardiac fibrosis Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 201000002793 renal fibrosis Diseases 0.000 claims 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003457 sulfones Chemical class 0.000 claims 1
- PYHOFAHZHOBVGV-UHFFFAOYSA-N triazane Chemical compound NNN PYHOFAHZHOBVGV-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662418833P | 2016-11-08 | 2016-11-08 | |
| US62/418,833 | 2016-11-08 | ||
| PCT/US2017/060392 WO2018089360A1 (en) | 2016-11-08 | 2017-11-07 | Pyrrole amides as alpha v integrin inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020500182A JP2020500182A (ja) | 2020-01-09 |
| JP2020500182A5 true JP2020500182A5 (https=) | 2020-12-17 |
| JP7220653B2 JP7220653B2 (ja) | 2023-02-10 |
Family
ID=60409438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019523772A Active JP7220653B2 (ja) | 2016-11-08 | 2017-11-07 | アルファｖインテグリン阻害剤としてのピロールアミド |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10717736B2 (https=) |
| EP (1) | EP3538528B1 (https=) |
| JP (1) | JP7220653B2 (https=) |
| KR (1) | KR102515507B1 (https=) |
| CN (1) | CN110139864B (https=) |
| AU (1) | AU2017359030A1 (https=) |
| BR (1) | BR112019009293A2 (https=) |
| CA (1) | CA3042693A1 (https=) |
| CY (1) | CY1123893T1 (https=) |
| DK (1) | DK3538528T3 (https=) |
| EA (1) | EA201991124A1 (https=) |
| ES (1) | ES2852351T3 (https=) |
| HR (1) | HRP20210228T1 (https=) |
| HU (1) | HUE053620T2 (https=) |
| IL (1) | IL266469A (https=) |
| LT (1) | LT3538528T (https=) |
| MX (1) | MX377293B (https=) |
| PL (1) | PL3538528T3 (https=) |
| PT (1) | PT3538528T (https=) |
| RS (1) | RS61453B1 (https=) |
| SI (1) | SI3538528T1 (https=) |
| SM (1) | SMT202100089T1 (https=) |
| WO (1) | WO2018089360A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109996541A (zh) | 2016-09-07 | 2019-07-09 | 普利安特治疗公司 | N-酰基氨基酸化合物及其使用方法 |
| AU2017359025A1 (en) * | 2016-11-08 | 2019-06-20 | Bristol-Myers Squibb Company | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha V integrin inhibitors |
| CN110177787A (zh) | 2016-12-29 | 2019-08-27 | 圣路易斯大学 | 整合素拮抗剂 |
| MA52117A (fr) | 2017-02-28 | 2022-04-06 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
| MA47697A (fr) | 2017-02-28 | 2020-01-08 | Morphic Therapeutic Inc | Inhibiteurs de l'(alpha-v)(bêta-6) intégrine |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| FI3844162T3 (fi) | 2018-08-29 | 2025-03-27 | Morphic Therapeutic Inc | Alfa v beeta6 -integriinin estäjiä |
| EP4086254B1 (en) | 2018-08-29 | 2024-12-18 | Morphic Therapeutic, Inc. | Integrin inhibitors |
| AU2019373242B2 (en) | 2018-10-30 | 2023-07-13 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| EP4541422A3 (en) | 2018-10-30 | 2025-06-25 | Gilead Sciences, Inc. | Quinoline derivatives as alpha4beta7 integrin inhibitors |
| KR102659859B1 (ko) | 2018-10-30 | 2024-04-25 | 길리애드 사이언시즈, 인코포레이티드 | 알파4β7 인테그린의 억제를 위한 화합물 |
| CN112969700B (zh) | 2018-10-30 | 2024-08-20 | 吉利德科学公司 | 作为α4β7整合素抑制剂的咪唑并吡啶衍生物 |
| KR102908219B1 (ko) | 2019-08-14 | 2026-01-08 | 길리애드 사이언시즈, 인코포레이티드 | 알파 4 베타 7 인테그린의 저해용 화합물 |
| CR20230472A (es) * | 2021-03-10 | 2024-03-21 | Dice Molecules Sv Inc | Inhibidores de integrina alpha v beta 6 y alpha v beta 1 y sus usos |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849736A (en) * | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
| IL118325A0 (en) * | 1995-05-25 | 1996-10-31 | Pont Merck And Pharmaceutical | Integrin receptor antagonists and pharmaceutical compositions containing them |
| ZA972195B (en) | 1996-03-15 | 1998-09-14 | Du Pont Merck Pharma | Spirocycle integrin inhibitors |
| EP1049693A1 (en) * | 1997-11-26 | 2000-11-08 | Du Pont Pharmaceuticals Company | 1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS $g(a) v?$g(b) 3? ANTAGONISTS |
| WO1999030709A1 (en) | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Integrin receptor antagonists |
| CZ20003672A3 (cs) | 1998-04-10 | 2001-08-15 | G. D. Searle & Co. | Heterocyklické glycyl-beta-alaninové deriváty jako agonisté vitronektinu |
| WO2000009503A1 (en) | 1998-08-13 | 2000-02-24 | Merck & Co., Inc. | Integrin receptor antagonists |
| AUPP646598A0 (en) | 1998-10-12 | 1998-11-05 | Fujisawa Pharmaceutical Co., Ltd. | New processes for producing alpha-alanine derivative |
| DE19939981A1 (de) | 1999-08-24 | 2001-03-01 | Merck Patent Gmbh | Neue Inhibitoren des Integrins alphavß3 |
| CZ20021508A3 (cs) * | 1999-11-08 | 2002-10-16 | Merck & Co., Inc. | Způsob výroby imidazolidinonových derivátů |
| GB0001447D0 (en) * | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
| NZ539682A (en) | 2001-01-29 | 2006-03-31 | Dimensional Pharm Inc | Substituted indoles and their use as integrin antagonists |
| DK1539739T3 (da) | 2002-08-16 | 2011-03-07 | Janssen Pharmaceutica Nv | Piperidinylforbindelser, der selektivt binder integriner |
| TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
| EP1667668B1 (en) | 2003-10-01 | 2008-07-02 | MERCK PATENT GmbH | Alfavbeta3 and alfavbeta6 integrin antagonists as antifibrotic agents |
| WO2006108040A1 (en) | 2005-04-05 | 2006-10-12 | Janssen Pharmaceutica, N.V. | Substituted indoles and their use as integrin antagonists |
| EP2049490A1 (en) | 2006-06-09 | 2009-04-22 | Astra Zeneca AB | N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl]-l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors |
| WO2008125811A1 (en) | 2007-04-11 | 2008-10-23 | Astrazeneca Ab | N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS |
| WO2011090929A1 (en) * | 2010-01-19 | 2011-07-28 | Theravance, Inc. | Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents |
| ITFI20100019A1 (it) | 2010-02-12 | 2011-08-13 | Univ Firenze | Inibitori peptidomimetici di integrine basati sull'1,2,3-triazolo per la diagnosi e terapia dei tumori. |
| NZ603789A (en) | 2010-05-26 | 2015-03-27 | Sunovion Pharmaceuticals Inc | Heteroaryl compounds and methods of use thereof |
| HRP20171873T1 (hr) * | 2013-02-07 | 2018-02-23 | Scifluor Life Sciences, Inc | Fluorinirani antagonisti integrina |
| GB201305668D0 (en) * | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417002D0 (en) * | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| KR102647026B1 (ko) | 2015-02-19 | 2024-03-12 | 사이플루어 라이프 사이언시즈, 인크 | 플루오르화 테트라히드로나프티리디닐 노난산 유도체 및 이의 용도 |
| CA2981371A1 (en) | 2015-03-10 | 2016-09-15 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
-
2017
- 2017-11-07 SI SI201730618T patent/SI3538528T1/sl unknown
- 2017-11-07 KR KR1020197016078A patent/KR102515507B1/ko active Active
- 2017-11-07 MX MX2019005233A patent/MX377293B/es active IP Right Grant
- 2017-11-07 RS RS20210206A patent/RS61453B1/sr unknown
- 2017-11-07 AU AU2017359030A patent/AU2017359030A1/en not_active Abandoned
- 2017-11-07 US US16/347,826 patent/US10717736B2/en active Active
- 2017-11-07 EA EA201991124A patent/EA201991124A1/ru unknown
- 2017-11-07 PL PL17801236T patent/PL3538528T3/pl unknown
- 2017-11-07 HR HRP20210228TT patent/HRP20210228T1/hr unknown
- 2017-11-07 CN CN201780082138.2A patent/CN110139864B/zh active Active
- 2017-11-07 JP JP2019523772A patent/JP7220653B2/ja active Active
- 2017-11-07 EP EP17801236.5A patent/EP3538528B1/en active Active
- 2017-11-07 WO PCT/US2017/060392 patent/WO2018089360A1/en not_active Ceased
- 2017-11-07 HU HUE17801236A patent/HUE053620T2/hu unknown
- 2017-11-07 DK DK17801236.5T patent/DK3538528T3/da active
- 2017-11-07 BR BR112019009293A patent/BR112019009293A2/pt not_active Application Discontinuation
- 2017-11-07 CA CA3042693A patent/CA3042693A1/en not_active Abandoned
- 2017-11-07 PT PT178012365T patent/PT3538528T/pt unknown
- 2017-11-07 ES ES17801236T patent/ES2852351T3/es active Active
- 2017-11-07 SM SM20210089T patent/SMT202100089T1/it unknown
- 2017-11-07 LT LTEP17801236.5T patent/LT3538528T/lt unknown
-
2019
- 2019-05-06 IL IL266469A patent/IL266469A/en unknown
-
2021
- 2021-02-23 CY CY20211100149T patent/CY1123893T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020500182A5 (https=) | ||
| JP2019094345A5 (https=) | ||
| JP2014518882A5 (https=) | ||
| JP2018507890A5 (https=) | ||
| JP2016506958A5 (https=) | ||
| RU2013154412A (ru) | Аминопиримидины в качестве ингибиторов syc | |
| RU2006134020A (ru) | Конденсированные производные пиразола | |
| JP2015514806A5 (https=) | ||
| JP2019537605A5 (https=) | ||
| JP2018507877A5 (https=) | ||
| JP2014511891A5 (https=) | ||
| JP2019518741A5 (https=) | ||
| RU2011144763A (ru) | 6-(3-азабицикло[3.1.0]гекс-3-ил)-2-фенилпиримидины | |
| JP2011137006A5 (https=) | ||
| RU2015118647A (ru) | Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr | |
| JP2006515858A5 (https=) | ||
| JP2015523383A5 (https=) | ||
| JP2015514808A5 (https=) | ||
| JP2016506960A5 (https=) | ||
| JP2014511892A5 (https=) | ||
| JP2016530259A5 (https=) | ||
| SI3166925T1 (en) | Isoindoline derivatives for use in treating a viral infection | |
| JP2017502940A5 (https=) | ||
| RU2012136451A (ru) | Композиции и способы улучшения активности протеасомы | |
| JP2004516314A5 (https=) |